SCHEMBL2669616

SCHEMBL2669616

CCCCOCCOc1ccc(CC(C(=O)OC)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.49
▸ ESR2 Q92731 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ RARB P10826 2/20 0.43
▸ MAPK1 P28482 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ HRH3 Q9Y5N1 2/20 0.42
▸ PPARG P37231 1/20 0.42
▸ PPARD Q03181 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ GCGR P47871 2/20 0.41
▸ ADCY6 O43306 1/20 0.41
▸ ADCY3 O60266 1/20 0.41
▸ ADCY9 O60503 1/20 0.41
▸ ADCY5 O95622 1/20 0.41
▸ ADCY8 P40145 1/20 0.41
▸ ADCY7 P51828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669746 0.97 ESR1 (0.50) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL2669617 0.94 ESR1 (0.54) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL11999235 0.90 ESR1 (0.54) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL2669618 0.89 LMNA (0.49) ALDH1A1MEN1KMT2ALMNARARB
SCHEMBL2669728 0.86 LMNA (0.50) ALDH1A1MEN1KMT2ALMNARARB
SCHEMBL2659405 0.85 KMT2A (0.53) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL2656926 0.85 KMT2A (0.53) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL11999238 0.83 LMNA (0.54) KMT2ALMNASMN1; SMN2PPARGPPARD
SCHEMBL2658018 0.79 KMT2A (0.58) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL2669634 0.79 GCGR (0.45) ALDH1A1MEN1KMT2AHRH3GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 — — US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 — — US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 — — US disclosed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 — — EP disclosed
EP-2129654-B1 ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2014-05-28 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ESR1 1070/4885ESR2 685/4885ALDH1A1 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback